Combination benefit of amlodipine plus atorvastatin treatment on carotid atherosclerosis in Zucker metabolic rats

Hiromi Kawai, Tomoko Kurata, Kentaro Deguchi, Shoko Deguchi, Toru Yamashita, Yasuyuki Ohta, Yoshio Omote, Syoichiro Kono, Koji Abe

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives: Obesity is the major risk factor for metabolic syndrome and atherosclerotic cardiocerebrovascular diseases. Methods: We studied effects of amlodipine, atorvastatin, and their combination on carotid arteriosclerotic processes in a metabolic syndrome model of Zucker fatty rats. Zucker fatty rats were treated with vehicle, amlodipine, atorvastatin, or combination amlodipine plus atorvastatin for 28 days. Results: Compared with the single treatment with amlodipine or atorvastatin, the combination of amlodipine plus atorvastatin treatment prevented arteriosclerotic processes, and induced a strong recovery of Sirtuin1 (Sirt1) expression and a marked reduction in p53, p21, and monocyte chemoattractant protein-1 (MCP-1). Discussion: As Sirt1 is a longevity gene that prevents endothelial atherosclerotic processes, and p53, p21, and MCP-1 play pivotal roles in the initiation and development of atherosclerosis, these data suggest a strong synergistic benefit of combination therapy with amlodipine and atorvastatin for preventing atherosclerotic processes, and potentially reducing the clinical risk of cerebrovascular events in metabolic obesity patients.

Original languageEnglish
Pages (from-to)181-186
Number of pages6
JournalNeurological Research
Volume35
Issue number2
DOIs
Publication statusPublished - Mar 2013

Keywords

  • Amlodipine
  • Atorvastatin
  • Common carotid artery
  • Zucker fatty rat

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Combination benefit of amlodipine plus atorvastatin treatment on carotid atherosclerosis in Zucker metabolic rats'. Together they form a unique fingerprint.

  • Cite this